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Abstract. In contrast to the traditional biochemical study of
single proteins or isolated pathways in health and disease,
technical advances in the high-throughput screening of
peptides by mass spectrometry have established new ways of
identifying entire cellular protein populations in one swift
analytical approach. This review discusses the recent progress
in the biochemical analysis of skeletal muscle extracts and
outlines the mass spectrometry-based proteomics approach
for studying muscle tissues in normal and pathobiochemical
processes using peptide mass fingerprinting. Individual
topics covered include the most commonly inherited muscle
disease, X-linked muscular dystrophy, the physiological
process of fast-to-slow fibre transformation, and the role of
fibre degeneration in age-related muscle wasting. Recent
proteomic profiling studies of dystrophic muscles have
revealed new disease markers in dystrophin-deficient fibres,
such as adenylate kinase, the Ca2+-binding protein regucalcin
and the small heat shock protein cvHSP. Since these muscle
proteins are of low abundance, they have not previously been
identified as biomarkers of muscular dystrophy, illustrating
the increased sensitivity of modern mass spectrometric
techniques. This review outlines comparative proteomic
techniques that employ conventional labeling methods, such
as Coomassie- or silver-staining. In addition, the most
advanced proteomic screening approach currently available,
fluorescence difference in-gel electrophoresis, is described
and its potential for studying muscle proteomes is critically
examined. As an alternative suggestion, the two-dimensional
analysis of different protein samples separated in parallel on
a single second dimension gel is introduced and the useful-
ness of this technique for direct comparative investigations is
explained. The potential of studying protein complex
formation by intraproteomics, estimating the composition of
subcellular fraction by subproteomics, and analyzing total
muscle protein extracts by mass spectrometry-based
proteomics, is enormous. Proteomics is one of the most
promising new analytical ways of comparing large muscle
protein complements and has the potential to decisively
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1. Introduction
The availability of mass spectrometry (MS)-based proteomics
for the large-scale screening of proteins has decisively
enhanced the research capabilities of the modern biochemical
laboratory (1). In contrast to the traditional biochemical
approach of studying individual peptide species, isolated
protein complexes or functionally linked groups of bio-
molecules, technical advances in the high-throughput MS
screening of peptides now enable bioresearchers to identify
entire protein complements (2-9). Although 2-D gel electro-
phoretic separation techniques represent the most frequently
chosen separation strategy for the proteomics of soluble
components (10), insoluble membrane proteins can also be
studied using liquid chromatography methodology (11).
Since post-translational modifications play an essential role
in protein sorting and function, the characterisation of protein
modifications has also been intensively studied by modern
MS-based proteomics (12-14). Hence, proteomic profiling
currently represents the most powerful tool for the fast
identification of novel disease markers that are involved in
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neuromuscular disorders (15) and age-dependent muscle
wasting (16). Based on initial proteomic data, new
biomarkers can then be characterised in detail by standard
biochemical, physiological and cell biological methods, and
their potential for improving diagnostic procedures and/or
therapeutic approaches can be evaluated. 
A general hierarchy of biological organization from gene
to functional cellular unit is generally accepted now, which
includes the genome, the transcriptome, subproteomes and
the proteome. In the case of skeletal muscle fibres, the motor
neuron and all its inverted muscle fibres, usually termed motor
unit, represent the functional biological basis of the excitation-
contraction-relaxation cycle. In addition, skeletal muscle
fibres are also major players in the maintenance of heat
homeostasis and metabolic integration (17). Based on
biochemical and physiological criteria, skeletal muscles can
be divided into predominantly fast- or slow-twitching fibre
populations. Since changes in neuromuscular activity or
alterations in the mechanical loading conditions may severely
affect skeletal muscle fibre composition (18-20), these
biological factors have to be taken into account when one
performs the comparative proteomic profiling of a diseased
or aged muscle. The fact that muscle gene expression, protein
levels and isoform patterns are closely related to innervation
is illustrated by two important experimental findings. Firstly,
the physical disconnection between a fibre unit and its
respective motor neuron triggers rapid fibre atrophy (21) and
secondly, artificial electro-stimulation causes pronounced
changes in muscle activity (22). For example, the long-term
dennervation of the mature rat extensor digitorum longus
muscle triggers a 95% decrease in isometric contractile force
and a two-third loss in muscle tissue mass within a month (23).
This clearly illustrates the importance of judging muscle
pathobiochemistry in the context of the essential nerve-muscle
connection. Furthermore, studies on chronic electro-stimulation
of fast muscle fibres, resistance training, endurance training,
immobilization, and zero-gravity environments have shown
that the nutritional supply and hormonal factors are also
extremely important for skeletal muscle performance
(18-20,24,25). These factors have to be properly integrated
into the overall biomolecular analysis of diseased muscle
specimens, if one wants to properly understand the impact of
changes caused by primary genetic mutations or acquired
cellular abnormalities that impair the integrity of motor fibres.
Fig. 1 outlines the organizational hierarchy within a
muscle, and the reference to the existence of a physiologically
active motor unit takes into account that the adaptive
response of skeletal muscle fibres depends, at least partially,
on neuromuscular activity (18). One can therefore argue that
‘the skeletal muscle proteome’, as a distinct and unchangeable
biological entity, does not exist. This is due to constant
adaptive changes within the expression profile of all major
groups of muscle proteins, thereby affecting the functional,
structural and metabolic property of any given skeletal
muscle under investigation. In addition, because of technical
limitations in separating proteins of very different properties
and expression levels, the biochemical isolation of the skeletal
muscle proteome can only represent the near-to-total fibre
proteome (26). In the case of the human genome, it is
estimated that the approximate 30,000 identified genes
produce several 100,000 proteins, which is based on alternative
splicing processes and post-translational modifications (27).
Even the most advanced fluorescence difference gel electro-
phoretic approaches for studying entire skeletal muscle
proteomes are not capable of presenting more than a few
thousand individual protein species. It is estimated that the
expression levels between proteins probably differ by several
orders of magnitude, therefore no one biochemical separation
technique is currently capable of resolving the entire muscle
protein complement. However, despite these currently
insurmountable biological and analytical difficulties, the
combination of high-resolution 2-D gel electrophoresis with
the application of novel fluorescence protein dyes can
nevertheless give an excellent overview of major pathological
changes in muscle diseases. In combination with protein
analyses by high-throughput liquid chromatography (28) and
comparison to data from transcriptomic studies, new disease
markers can be readily identified at a drastically accelerated
rate as compared to conventional biochemical approaches.
2. Mass spectrometry-based proteomics
The development of monoclonal antibodies as unique bio-
chemical tools for the identification of proteins using
immunochemical techniques, such as immunoblotting, has
dominated biological research for over a decade (29).
However, this relatively expensive screening approach with
libraries of highly specific antibodies has more recently been
replaced by MS-based identification methods (1-7). Although
immunoblotting with suitable antibodies and direct peptide
sequencing using automated procedures such as Edman
degradation can be integrated into proteomic analyses, the
most common analytical high-throughput technique is
peptide mass fingerprinting (PMF). The development of
MALDI-ToF and ESI-MS/MS methodology has put MS-
based proteomics at the forefront for large-scale comparative
studies (8,9,30,31). The flowchart shown in Fig. 2 outlines a
typical experimental set-up for the proteomic profiling of
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Figure 1. Diagrammatic presentation of the position of the skeletal muscle
proteome within the organizational hierarchy of a motor unit. While the
muscle genome stays relatively constant over a lifetime, the fibre proteome
is in constant flux and undergoes pathobiochemical alterations or adapts to
modified functional demands.
skeletal muscle specimens. Comparative proteomics is
concerned with the qualitative and quantitative comparison
of entire protein complements under varying biological
conditions (7). Skeletal muscle proteomics in particular
involves the global biochemical analysis of protein expression
patterns in contractile fibres using standard techniques to
separate and characterise muscle proteins, and then identify
these protein species by interlinking with 2-D gel electro-
phoretic databanks and/or protein sequence databanks
(32,33). The skeletal muscle proteome is defined as the protein
complement expressed by a given muscle fibre genome (26). 
If the term ‘proteome analysis’ is used, one usually
assumes that this involves total tissue extracts as starting
material. The proteomic profiling of subcellular fractions is
therefore referred to as subproteomics. In the case of muscle,
the comparative proteomic screening of mitochondria, the
sarcoplasmic reticulum or the sarcolemma falls therefore
under this category. If the oligomeric status of proteins or
robust heterogeneous protein-protein interactions is surveyed
by proteomic technology, this analytical approach is usually
called intraproteomics. As outlined in Fig. 2, individual
muscle proteins within the entire proteome, the various sub-
proteomes or the intraproteome differ greatly in their relative
abundance, solubility, charge and size. These physical
parameters are exploited in the biochemical separation of
muscle proteins. Besides various chromatographical
methods, the most common high-resolution separation of the
skeletal muscle proteome is represented by 2-D gel electro-
phoresis. The application of isoelectric focusing in the first
dimension and sodium dodecyl sulfate polyacrylamide gel
electrophoresis in the second dimension is described below
in detail. Once muscle proteins have been properly separated,
PMF analysis is performed by MS in order to identify
individual proteins (9,30). Fig. 3 shows the identifying MS
spectrum of the muscle component vimentin using PMF of
in-gel digests. This technique relies on the assumption that
the controlled digestion of a distinct protein species results in
the generation of a unique set of peptides that exhibit a specific
combination of molecular masses (31). The comparison of the
determined molecular masses of a sub-set of trypsin-generated
peptides with predicted values of vimentin fragments led to
the identification of this intermediate filament protein, and its
increased expression in muscular dystrophy (34,35). The
peptide population shown in the MS spectrum of Fig. 3
represents 11 matching sequences with a 26% coverage of
the vimentin protein from Mus musculus. The MS data
predict a pI-value of 5.09 and a relative molecular mass of
53.6 kDa for the electrophoretically separated mouse muscle
vimentin molecule. Thus, PMF can be employed for the
identification of an unknown protein by performing a compu-
tational comparison of its trypsin-generated constituent
fragment masses to the theoretical in silico generated peptide
masses. Exhaustive trypsin treatment of a typical skeletal
muscle protein usually results in peptides ranging from 500
to 2,500 kDa, as illustrated in Fig. 3. This method has
initially been described by Henzel et al (36) and is now
widely employed in the routine identification of proteins
(37). Since the fingerprinting technique is a comparative
method, an important prerequisite for the identification of a
specific peptide mixture is the existence of a comprehensive
and ideally species-specific protein- or DNA-based sequence
databank for the biological material under investigation (33).
MALDI-ToF MS analysis of a protein sample involves
the irradiation of a co-precipitate, consisting of the peptide or
peptides of choice and a suitable UV-light absorbing matrix
by a nano-second laser pulse (30,31). For instrumental and
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Figure 2. Flowchart of the proteomic profiling approach to study skeletal muscles. In order to study the entire accessible protein complement of a skeletal
muscle, the protein fraction is extracted from crude fibre preparations or suitable subcellular fractions and then separated according to electrical charge and
molecular mass. Individual protein species can be identified by peptide mass fingerprinting (PMF) using MALDI-ToF MS or ESI-MS/MS techniques.
Alternatively, N-terminal peptide sequencing employing automated Edman degradation, immunoblotting surveys using libraries of monoclonal antibodies, or
the comparison of the 2-D spot pattern with international databanks can be helpful in determining the identity of a novel biomarker protein.
technical details, there are excellent books on the biological
application of MS available (38-41). The underlying technical
principle of a ToF mass spectrometer is that ions with a
different mass/charge (m/z) ratio will traverse a constant
electric field in a time that depends strictly upon their m/z
ratios. Thus, for a proper MALDI-ToF MS analysis, a group
of biological ions must be subjected to the same electrical
field and most of the laser energy has to be absorbed by the
matrix, so that the biomolecules under investigation are not
excessively fragmented. Following acceleration in the electric
field, the ionized peptides enter a flight tube, where molecules
separate according to their mass to charge ratio. This results
in differential signals for individual ions when they reach the
detector. The analytical measuring time is in the minute range
and the sample amount needed for a distinct signal is in the
pmol range, making MALDI-ToF MS technology an
indispensable tool of modern protein biochemistry. As with
any other biochemical technique, contaminants and various
analytical variables may negatively affect the MS profiling.
Problems can be due to the actual physico-chemical properties
of the protein to be analysed, such as the predominant
hydrophobic or hydrophilic properties of amino acid side
chains. For a detailed description of MS methodology used in
modern biochemistry, including the ESI-MS/MS technique
for the direct determination of peptide sequences, please
consult a recent review by Domon and Aebersold (9).
In the case of PMF, a very important parameter to be
taken into account is the method of protein digestion. The
publicly available search engine Mascot from Matrix Science
(http://www.matrixscience.com) can handle 17 different
enzymatic protocols. The most common method is trypsination
of the protein of interest using sequencing-grade trypsin
preparations. Subsequently, the proper mixing of generated
peptides with a suitable matrix has to be accomplished,
whereby the right concentration ratio and compatibility of
matrix and peptide sample has to be taken into account. The
choice of matrix for optimum MALDI results is therefore
very important. Common matrices for protein work are
·-cyano-4-hydroxycinnamic acid, 3,5-dimethoxy-4-hydroxy-
cinnamic acid and 2,5-dihydroxybenzoic acid (31). In
addition, a low quantity of sample specimens will result in a
weak detector signal that may lead to an insufficient analytical
spectrum. The MS analysis of peptides generated from
protein species that have originally been derived from crude
protein mixtures might also be complicated by the presence
of interfering chemicals. During solubilization procedures
and the gel electrophoretic separation of muscle proteins for
example, a high concentration of contaminants may associate
with peptide fragments, such as Tris buffer molecules, urea,
dithiothreitol or sodium dodecyl sulfate. If these contaminants
interfere with a proper MS analysis, samples have to be pre-
cleaned to remove non-biomolecular components.
Besides MALDI-ToF technology, other high-throughput
approaches for the swift identification of proteins are ESI-
MS/MS techniques, automated N-terminal sequencing or
immunoblotting/dot-blotting with monoclonal antibodies.
These well-established biochemical techniques are very
reliable and routinely used in the initial screening procedure
of proteins or employed in the confirmation of MALDI-ToF
MS-generated lists of identified protein candidates. In
addition, although not as reliable as direct peptide sequencing
or ESI-MS/MS analysis, the simple comparison of the
relatively unique combination of the isoelectric point and
relative molecular mass of a particular 2-D protein spot with
existing 2-D protein databanks can be employed to identify a
protein (32). If the pI-value and the molecular mass of an
unknown protein result in a positive hit in a tissue-specific
databank, such as the SWISS-2DPAGE database (33), it is
highly recommended that these findings be confirmed by
immunoblotting. If no suitable antibodies to the skeletal
muscle protein in question are available, automated N-terminal
peptide sequencing can be employed as an alternative
method. Besides choosing the right identification tools in
comparative proteomic studies, it is also crucial to keep in
mind that the manipulation of tissue extracts may introduce
artifacts. In skeletal muscle preparations, the presence of the
highly abundant proteins myosin, actin, troponin and tropo-
myosin presents a serious problem during the 2-D separation
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Figure 3. Identification of vimentin by peptide mass fingerprinting. Shown is the MALDI-ToF MS spectrum of a 2-D spot from mouse skeletal muscle
following in-gel digestion. The scan exhibits the unique peptide population generated from the trypsination of the cytoskeletal protein vimentin with 11
matching sequences that account for a 26% coverage of the protein.
of the fibre proteome. Pre-fractionation techniques have
recently been developed that remove the major class of
contractile muscle proteins prior to electrophoresis (42), but
comparative proteomic approaches should avoid extensive
fractionation schemes so that they can achieve a true
representation of the skeletal muscle proteome from normal
versus pathological specimens. Since any extraction procedures
or subcellular fractionation steps may introduce, by their very
nature, undesirable modifications in the composition of tissue
preparations, it is recommended that crude skeletal muscle
fibre preparations be used. This enables the best comparative
way to investigate the entire accessible proteome of normal
versus diseased muscles.
3. Biomarker identification and comparative proteomics
Comparative proteomics is a novel approach for determining
qualitative and quantitative differences in the protein
complement of a specific type of tissue under different
biological or pathological conditions (1-7). Proteomics
technology suggests itself for a comprehensive study of the
muscle protein phenotype (26), since distinct alterations in
the protein expression pattern of skeletal muscle fibres are
involved in a variety of inherited neuromuscular disorders,
acquired autoimmune diseases, pharmacogenetic afflictions,
age-related complications, the biomedical design of cardiac
assist pumps and physiological adaptations to changed
functional demands (43). The search for new biomarkers of
neuromuscular diseases and age-dependent fibre wasting in
humans will be a difficult and complex task. In contrast to
inbred animal strains used for disease model research, biopsy
material from human patients is considerably more hetero-
geneous. Inter-individual differences between humans of the
same age, gender and ethnical background are due to variations
in life style, environmental exposure, nutrition, disease history
and genetics. In addition, biopsy material taken at advanced
stages of a muscle disease may not exhibit specific enough
differences in the changed expression of disease markers,
because many neuromuscular disorders may share common
pathophysiological pathways during end-stage pathology (43). 
In contrast to the human genome, the skeletal muscle
proteome is constantly changing during a patient's lifetime,
which constitutes another problem in the search for robust
biomarkers. Clinically most human diseases have to be
considered heterogeneous. For example sarcopenia, the age-
related decline in skeletal muscle strength and mass, is a
heterogeneous muscle-wasting disorder with considerable
variations in symptoms and severity (44-46). Different
mutations in the same gene may trigger two different muscle
pathologies, e.g. primary genetic abnormalities in the
ryanodine receptor Ca2+-release channel of the sarcoplasmic
reticulum may cause central core disease or convey suscepti-
bility to the pharmacogenetic disorder malignant hyperthermia
(47,48). On the other hand, mutations in two different genes
may result in a very similar disease process with comparable
symptoms, e.g. certain mutations in the dihydropyridine
receptor or the ryanodine receptor may be both associated
with malignant hyperthermia (48,49). Thus, many technical
and biological obstacles have to be overcome and certain
minimum criteria established before one can properly integrate
a new biomarker into the existing diagnostic scheme of
muscle pathology. A robust and reliable biomarker should
be: i) soluble for ease of access, ii) relatively abundant so
that unfavorable signal-to-noise ratios do not become a
problem, iii) not greatly different in density between
individual control samples so that its statistical evaluation
does not represent a complex problem, iv) of consistent
concentration in non-disease samples over time, and v)
highly disease-specific so that the existence of common
pathophysiological pathways does not lead to a misdiagnosis.
2-D gel electrophoresis in combination with high-throughput
protein identification via PMF can be conveniently used for
studying changes in the skeletal muscle proteome. Therefore,
another important biochemical criteria for a good biomarker
is that the protein must be sensitive to common proteolytic
procedures, such as trypsination, for its proper initial
identification. Besides cataloging skeletal muscle proteins,
recent applications of muscle proteomics have led to the
identification of changes in the skeletal muscle proteome
during aging, muscular dystrophy, and fibre transformation,
as described below in detail. Thus, the worldwide effort to
find new disease markers should soon translate into
improved diagnostic procedures and the identification of
novel therapeutic targets for the future treatment of muscle
diseases. 
Standard comparative proteomics usually uses two
separate gels, which represent a control specimen and a
diseased or conditioned sample for subsequent densitometric
analysis (3). As illustrated in Fig. 4, besides using two
separate gels, samples can also be analysed in parallel or as a
pre-labeled mixture on one 2-D slab gel. The more advanced
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Figure 4. Diagrammatic comparison between 3 types of gel electrophoretic
methods used in skeletal muscle proteomics. Traditionally, as shown in
panel A, different proteomes are displayed on different 2-D gels and then
compared by densitometric analysis. Alternatively, to avoid statistical errors
due to unavoidable gel-to-gel variations, both first dimension gels can be
separated in parallel on the same 2-D slab gel (B). Panel C outlines the most
advanced comparative proteomic approach using differential fluorescent
tagging of proteomes prior to their separation on the same 2-D gel.
Difference in-gel electrophoresis (DIGE) is one of the most sensitive
detection techniques available for comparative biochemical studies in the
search for novel biomarkers of neuromuscular diseases.
difference gel electrophoresis approach, now commonly
referred to as DIGE, exploits the differential fluorescence
labeling of more than one protein complement, which are
then separated on the same gel system (50-53). This
technique considerably reduces gel-to-gel variation, but is
also extremely costly with respect to fluorescence tagging
and licensing of the analysis software package (50). The
DIGE method is based on the use of multiple fluorescent dyes
for labeling protein samples prior to their electrophoretic
separation (50-53). The three most commonly used Cy dyes
are Cy2, Cy3 and Cy5, which are excited with lasers at 488,
532 and 635 nm, respectively. Usually, the control or normal
sample is labeled with Cy3 and the disease or treated sample
is labeled with Cy5. A pooled mixture of both samples is then
labeled with the Cy2 dye and serves as an internal standard.
All three differentially labeled protein suspensions are then
separated on the same 2-D gel and a multiplexed image is
analysed by comparing any specific protein spot to its own
internal standard. As illustrative examples, the differential
fluorescence DIGE gel staining pattern of unstimulated versus
chronic low-frequency stimulated tibialis anterior muscle
(Fig. 5A) and of normal versus dystrophic diaphragm fibres
(Fig. 5B-G) is shown. Although usually the Cy2 dye is used
for the labeling of the pooled standard, any combination of
the Cy2, Cy3 and Cy5 dyes can be employed in comparative
DIGE studies. In Fig. 5A, the Cy2-labeled 50:50 mixture of
both muscle type proteomes has been used as an internal
standard, while in Fig. 5D and G the Cy5-pooled fraction has
been employed for standardization of expression levels. Both
analyses are discussed in detail in subsequent sections on
muscular dystrophy and muscle plasticity. 
The analysis of fluorescence labeling patterns by 2-D
DIGE software programmes results in a list of the ratio of
relative protein expression. Compared to conventional
protein dyes, such as Coomassie or silver, which usually
visualize not more than a few hundred protein species, the
fluorescent DIGE method is capable of recognizing thousands
of muscle proteins in large 2-D-gel systems. Using multi-gel
electrophoresis apparatuses that can accommodate 6 to 12
individual DIGE gels for a parallel run, all necessary data
points can be generated in one swift analytical procedure.
Once all the different preparative steps have been optimized,
the comparative densitometric analysis of protein expression
in a normal versus disease proteome can be accomplished
within a week. The protein identity of 2-D spots with a
drastically changed density can then be determined by PMF
using MALDI-ToF MS or ESI-MS/MS. To confirm the
identity of a specific protein and to further characterise
the extent of expression changes, immunoblotting can be
employed. 
Although the fluorescent DIGE technique is extremely
sensitive and widely applicable to comparative proteomics
(50-53), it is also very expensive with respect to both running
costs and the need for specialized equipment. Here, we outline
an alternative procedure for a cost-effective comparative
proteomic analysis, which also reduces gel-to-gel variation
by using the same 2-D slab gel for the analysis of two separate
specimens, but without the need for differential fluorescence
labeling. This simplified method can be used to initially
optimize the sample preparation for comparative proteomics
prior to a more comprehensive DIGE analysis, or be employed
as an inexpensive alternative for a swift search of novel
biomarkers of diseases. The 2-in-1 2-D gel electrophoretic
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Figure 5. Fluorescence difference in-gel electrophoretic analysis of
transformed tibialis anterior muscle and dystrophic diaphragm muscle.
Shown is the differential fluorescent 2-D separation pattern of the fast-
twitch versus the transformed slow-twitch muscle proteome. The rabbit
tibialis anterior muscle has been chronic low-frequency stimulated (CLFS)
and then tagged with the fluor dye Cy5 or not electro-stimulated and then
tagged with the fluor dye Cy3. For internal standardization, the protein
complement from both specimens were mixed and labeled with the fluor dye
Cy2. Panels B-D illustrate representative 2-D gels of normal diaphragm,
dystrophic diaphragm and a mixed internal standard which have been
labeled with the fluorescent dyes Cy2, Cy3 and Cy5, respectively. The pH-
values of the first dimension gel system and molecular mass standards (in
kDa) of the second dimension are indicated on the top and on the left of the
panels, respectively. Panels E-G show enlargements of the three fluorescent
images of the fluor Cy dyes, clearly demonstrating a drastic reduction of the
cytosolic Ca2+-binding protein regucalcin in dystrophin-deficient muscle
fibres. Regucalcin (RC) is also referred to as senescence marker protein of
30 kDa (SMP-30). DIGE gels of the skeletal muscle proteome can separate
several thousand individual protein species making it the preferred method
for the initial discovery of new biomarkers. 
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Figure 6. Comparison of the 2-D separation pattern of the fast-twitch versus
the slow-twitch muscle proteome. Shown are separate Coomassie-stained 2-
D gels of the rabbit tibialis anterior (A) and soleus (B) muscle proteome. As
outlined in the diagram of Fig. 4, in order to avoid extensive gel-to-gel
variations, both first dimension gels can be run on the same 2-D slab gel, as
shown in the silver-stained gels of fast and slow fibres in panels (C) and (D).
The pH-values of the first dimension gel systems and molecular mass
standards (in kDa) of the second dimension gels are indicated on the top and
on the left of the panels, respectively.
Figure 7. Flowchart of comparative proteomic profiling of skeletal muscle. For a cost- and time-effective initial analysis of two different muscle proteomes,
fibre extracts can be first studied by a 2-in-1 slab gel approach, as diagrammatically shown in Fig. 4. Interesting candidate 2-D spots with a drastically
changed expression level can then be analysed by MALDI-ToF MS and/or ESI-MS/MS techniques. Based on these findings, a more detailed comparative
proteomics screening can be performed using the fluorescence DIGE method, as shown in the 2-D gels in Fig. 5.
method has recently been successfully applied to the
proteomic analysis of chronic low-frequency-stimulated
muscle fibres (54), as discussed in detail below. Since skeletal
muscle is a relatively tough tissue for preparing cell extracts
and because muscle fibres contain many problematic protein
species with respect to an efficient 2-D gel electrophoretic
separation, muscle proteomics is accompanied by an array of
technical problems. However, the proper optimization of the
initial sample preparation step can at least partially overcome
these difficulties. Studies over the last few years have clearly
demonstrated that 2-D gel electrophoresis and MS-based
proteomics can be used for the comparative screening of
highly complex mammalian tissues. To illustrate this point,
we show here the findings of a comparative electrophoresis
analysis of total tissue extracts from slow and fast muscle
fibres on one 2-D slab gel. Fig. 6 shows that this technique is
capable of detecting distinct differences in varying protein
phenotypes. The conventional comparison using two
separate 2-D gels and Coomassie-staining is illustrated in
Fig. 6A and B, and contrasted to the alternative method
employing comparative 2-in-1 2-D gel electrophoresis with
silver- staining (Fig. 6C and D). The protein spot pattern
exhibits distinct differences between tibialis anterior and
soleus preparations. The protein expression profiling of
different fibre types shown here agrees with the
physiological and biochemical specialisation of muscles with
unique contractile capabilities (18-20). How the alternative
2-in-1 gel electro-phoresis method can be integrated into a
comparative proteomic approach, and be used as a simplified
and cost-effective first step in the characterisation of a
pathological specimen, is outlined in the flow chart of Fig. 7.
4. Skeletal muscle proteomics
Skeletal muscle proteomics represents a new analytical tool
for the cataloging of extractable protein components and the
determination of fibre-specific expression patterns (26). In
contrast to soluble biological materials and soft tissues,
skeletal muscle fibres represent an extremely tough tissue
consisting of gigantic cellular structures. A healthy skeletal
muscle fibre is a long, cylindrical and multi-nucleated cellular
unit, which is usually 10 to 100 μm in diameter and may
vary in length from millimeters to centimeters (17).
Approximately fifty percent of a muscle fibre's protein
content is made up of the contractile machinery, mostly
consisting of myosin complexes of the thick filaments and
actin strings of the thin filaments, as well as the regulatory
elements tropomyosin and the troponin complex. The
extremely high density of four protein species within one
class of tissue causes certain technical problems with the 2-D
gel electrophoretic separation of crude muscle extracts.
Although the main contractile muscle proteins exist in a
variety of isoforms (55), due to their similar molecular mass
and isoelectric point they form protein spot cluster within
similar areas in a standard 2-D slab gel. Thus, in order to
avoid cross-contamination and sample streaking during
electrophoretic separation, the total amount of protein
loading is more limited in muscle proteomics as compared to
other tissues. In addition, skeletal muscle fibres consist of
highly abundant and complex internal membrane systems
and organelles that contain a considerable amount of
relatively insoluble protein. The presence of contractile
proteins and integral receptor clusters therefore complicates
the proper separation of crude muscle extracts in 2-D gels.
Hence, the proteomic evaluation of complex mammalian
tissues, such as skeletal muscles, usually necessitates an initial
optimization procedure to solubilize the maximum amount of
individual classes of proteins. 
Although it is possible to load a considerably higher
concentration of muscle protein per first dimension gel, the
optimum amount of fibre protein per isoelectric focusing strip
is approximately 50 to 200 μg for a comparative proteomic
approach (34,35,54,56). Low protein concentrations (<50 μg
total protein) cause minimal cross-contamination between
individual 2-D spots, but the resulting staining pattern is
usually too weak for proper spot picking when conventional
non-fluorescent protein dyes are used. Loading with several
100 μg of protein has the opposite effect and results in the
appearance of many hundred distinct silver-stained muscle
protein spots. However, a very high protein concentration also
results in undesirable protein streaking in both gel dimensions.
Electrophoretic artifacts are caused by charged trains of
proteins in the first dimension and spot smearing due to
abnormal mobility shifts of high-density muscle proteins in
the second dimension. Even if these experimental considerations
are taken into account during pilot studies, a good 2-D
separation of muscle components is limited to proteins of
certain size and charge. For fluorescence DIGE analysis, the
recommended total protein concentration of all 3 labeled
protein complements is 150 μg (50-53), which is suitable for
comparative skeletal muscle proteomics (35).
Using standard 2-D gel procedures, very acidic muscle
proteins usually do not properly separate and form vertical
streaking at the pH 3.0 region. A high degree of hetero-
geneous glycosylation of the same protein backbone or the
presence of extensive hydrophobic peptide domains may
trigger considerable smearing of spot patterns. Since many
muscle surface proteins are highly glycosylated, the proteomic
profiling of the sarcolemma and transverse tubular membrane
systems can be complicated by the distortion of protein spots.
Integral membrane proteins with extensive hydrophobic
characteristics often cannot be sufficiently solubilized and
are therefore underrepresented in standard 2-D gels. Another
problem is presented by the proteomic profiling of very high-
molecular-mass proteins, since they do not enter the second
dimension in sufficient amounts for reproducible examinations.
For example, large proteins such as the ·1S-dihydropyridine
receptor of 175 kDa (57) and the myosin heavy chain of 220 kDa
(35,56) move into the second dimension after isoelectric
focusing, but very large proteins such as dystrophin of 427 kDa
or the ryanodine receptor Ca2+-release channel of 565 kDa do
not properly transfer from the first to the second slab gel
dimension. Thus, studies on the primary defective protein in
Duchenne muscular dystrophy (58) or the major mutant
factor involved in susceptibility to the pharmacogenetic
disorder malignant hyperthermia (49) cannot be executed
using conventional 2-D gel electrophoresis. However,
alternative diagonal 2-D gel techniques can be employed to
study extremely high-molecular-mass proteins, such as
triadin aggregates (59). These kinds of 2-D gels employ
combinations of native versus reducing conditions, or non-
reducing versus reducing dimensions, and can thus be used to
characterise protein oligomerisation (57).
Skeletal muscles represent the most abundant type of
mammalian tissue and display an enormous adaptive and
plastic potential. One of the most striking physiological and
biochemical characteristics of adult muscle fibers is their
intrinsic ability to adjust their structural, metabolic and
functional properties (19). Although fully differentiated and
functionally integrated within motor units, a mature muscle
can undergo extensive fibre type shifting in response to
changed physiological or pathophysiological demands (20).
In order to further our understanding of the molecular
mechanisms that underlie these biological adaptations and
modulations of muscle tissues during myogenesis, differen-
tiation, fibre aging and neuromuscular disease progression,
the improvement of reliable and swift methods for the
identification of muscle markers is essential. The introduction
of comparative transcriptomics and proteomics has decisively
enhanced the technical capabilities of myologists to find
novel muscle components that are involved in biological and
pathological processes. Since skeletal muscles are not only
involved in contraction, but also heat homeostasis and
metabolic integration, muscle proteomics is important for
understanding whole-body physiology. On the molecular level,
the array of biomolecules involved in elasticity, extensibility,
excitability and contractility of the muscular system have not
been fully elucidated (17). Possibly a more comprehensive
cataloging of muscle proteins via proteomic profiling may
identify novel protein factors involved in the maintenance
and regulation of skeletal muscle function. With the help of
sophisticated 2-D software analysis and statistics programmes,
it is now possible to perform proteomic investigations of
animal disease models with relatively limited amounts of
individual specimens. In stark contrast, clinical proteomic
studies must take into account inter-individual differences
between patients and therefore need higher experimental
repeats. 
Table I lists recent key studies that have used proteomics
to study skeletal muscle biology, showing how useful this new
systematic approach is for the identification of fibre protein
isoforms. Comprehensive 2-D reference maps of the skeletal
muscle proteome have been established for mouse (33), rat
(60), bovine (61,62) and human (63-65) tissues. Since fibre
type shifting plays an important role in various neuro-
muscular disorders and is also an important physiological
mechanism during normal adaptations to changed functional
demands, the cataloging of fast- and slow-twitch biomarkers
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Table I. Major skeletal muscle studies that have employed proteomic profiling.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Proteomic profiling Major finding Tissue/species Reference
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Protein cataloging Establishment of SWISS-2DPAGE Normal mouse skeletal muscle Sanchez et al (2001) (33)
database
Comprehensive 2-D reference map of Normal rat skeletal muscle Yan et al (2001) (60)
muscle proteome
Summary of identified muscle proteins Various Isfort (2002) (26)
using proteomics
2-D reference map of muscle proteome Normal human vastus lateralis Gelfi et al (2003) (63)
muscle
2-D reference map of muscle proteome Normal human deltoideus Capitanio et al (2005) (64)
versus vastus lateralis
2-D reference map of muscle proteome Normal human laryngeal muscle Li et al (2003) (65)
Comprehensive 2-D reference map of Normal bovine semitendinosus Bouley et al (2004) (61)
muscle proteome muscle
2-D reference map of alkaline proteins Normal bovine muscle Chaze et al (2006) (62)
in bovine muscle
Mitochondrial Proteomic comparison of mitochondrial Normal rat muscle versus heart Forner et al (2006) (70)
subproteome protein complement in muscle and heart
Muscle glycoproteome Identification of O-linked and Normal rat muscle Cieniewski-Bernard et al
N-acetylglucosamine proteins in muscle (2004) (71)
Fibre type cataloging Fibre type specific differences in protein Normal porcine longissimus Kim et al (2004) (66)
expression between red and white pork dorsi versus soleus muscle
meat
Fibre type specific differences in protein Normal and kyphoscoliotic Le Bihan et al (2004) (28);
expression between predominantly fast- muscle (2006) (67)
and slow-twitching mouse muscles
Fibre type specific differences in protein Normal rat extensor digitorum Okumura et al (2006) (68)
expression between predominantly fast- longus versus soleus muscle
and slow-twitching rat muscles
Fibre type specific differences in protein Normal rat gastrocnemius Gelfi et al (2006) (69)
expression between predominantly fast- versus soleus muscle
and slow-twitching rat muscles
Muscle transformation Identification of biomarkers during Chronic low-frequency- Donoghue et al (2005) (54)
fast-to-slow fibre transition process stimulated rabbit tibialis
anterior
Muscle growth Determination of muscle protein dynamics Normal chicken pectoralis Doherty et al (2004) (72) 
under conditions of rapid growth muscle
Myoblast differentiation Profile of the biochemical adaptations Mouse-derived C2C12 Kislinger et al (2005) (73)
associated with skeletal muscle myoblasts
development
Muscle exercise Identification of exercise-induced changes Mouse gastrocnemius muscle Takahashi and Kubota 
in the skeletal muscle proteome following swim exercise (2005) (74)
Skeletal muscle Determination of the effect of myostatin Heterozygote and homozygote Bouley et al (2005) (75)
hypertrophy deficiency on the fast muscle phenotype Belgian blue bulls semi-
tendinosus muscle
Immobilization-induced Profile of global protein changes during Immobilized rat soleus and Isfort et al 2002 (79,80)
muscular atrophy muscular atrophy following hindlimb tibialis anterior muscle
suspension
Muscular dystrophy Decrease in adenylate kinase in MDX mouse hindlimb muscle Ge et al (2003) (81)
dystrophin-deficient fibres
is an extremely important topic of modern muscle biology.
Fibre type cataloging has been performed for skeletal
muscles from various species, including the pig (66), mouse
(28,67) rabbit (54) and rat (68,69). Over the last few years,
many fundamental physiological, biochemical and cellular
processes associated with skeletal muscle fibres have been
studied by proteomics, such as the mitochondrial subproteome
(70), the muscle glycoproteome (71), muscle growth (72),
myoblast differentiation (73), exercise-induced changes in
the muscle proteome (74), muscle hypertrophy (75), the
effect of freezing conditions on meat storage (76), the effect
of dietary manipulations (77) and neuromuscular synapse
formation (78). Another important area of comparative
muscle proteomics is the study of diseased human tissue and
animal models. The focus has been on immobilization-
induced muscular atrophy (79,80), muscular dystrophy
(34,35,56,81,82), dysferlinopathy (83), mitochondrial muscle
disease (15) and sarcopenia (16,84-88).
For comparative studies it is extremely useful to employ
landmark 2-D spots to check equal loading conditions and
the reproducibility of gel electrophoretic separation techniques
(26,33,60,63). In our experience, key contractile and
regulatory proteins and certain metabolic marker enzymes
represent a sufficient number of easily recognisable spots to
quickly evaluate a 2-D-separated skeletal muscle proteome
(34,35,54,56). Useful muscle protein landmark spots include
the following relative unique combinations of the isoelectric
point and apparent molecular mass (35,56): pI5.8/70 kDa
(albumin), pI7.8/47 kDa (enolase), pI8.6/40 kDa (aldolase),
pI9.1/29 kDa (phosphoglycerate mutase), pI7.1/27 kDa
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Table I. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Proteomic profiling Major finding Tissue/species Reference
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Muscular dystrophy Determination of disturbed protein Cytosolic fraction of MDX Ge et al (2004) (82)
expression pattern in dystrophic mouse muscle
mice at different ages
Decreased expression of the luminal Mildly dystrophic MDX mouse Doran et al (2004) (56)
calcium-binding protein calsequestrin hindlimb muscle
in dystrophin-deficient fibres
Decreased expression of the cytosolic Severely dystrophic MDX Doran et al (2006) (34)
calcium-binding protein regucalcin mouse diaphragm
in dystrophin-deficient fibres
Drastic increase in the stress protein Severely dystrophic MDX Doran et al (2006) (35)
cvHSP in dystrophin-deficient fibres mouse diaphragm
Dysferlinopathy Profile of differentially expressed muscle Normal versus dysferlin- De Palma et al (2006) (83)
proteins in dysferlin-deficient fibres deficient human muscle
Mitochondrial muscle Concept of identifying novel protein Pathological human muscle Van de Heuvel et al
disease factors involved in neuromuscular (2003) (15)
diseases
Muscle aging 2-D reference map of effects of Young versus old human Cobon et al (2002) (16)
sarcopenia of old age muscle
Identification of age-dependent protein Young versus old rat muscle Kanski et al (2003) (84); 
nitration in skeletal muscle (2005) (85)
Optimisation of 2-D gel system for 18-month-old mouse hindlimb Chang et al (2003) (86)
studying the effect of aging on muscle
mitochondrial protein expression
Identification of changes in the skeletal 7-month versus 30-month-old Piec et al (2005) (87)
muscle proteome during aging rat gastrocnemius muscle
Determination of age-dependent changes Young verus old human Gelfi et al (2006) (88)
in the human skeletal muscle proteome vastus muscle
Effect of frozen storage Differential analysis of cod muscle Normal cod muscle Kjaergard et al (2006) (76)
on protein pattern stored under various conditions
Effect of dietary Profile of protein expression patterns in Normal rainbow trout muscle Martin et al (2003) (77)
manipulations rainbow trout following different diets
Neuromuscular Identification of secreted muscle Mouse soleus muscle and Gajendran et al (2002) (78)
synapse formation components involved in neuromuscular Sol8 myotubes
junction formation
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
(triosephosphate isomerase), pI4.7/33 kDa (tropomyosin 2),
pI6.1/30 kDa (slow troponin T), pI6.7/31 kDa (fast troponin T),
pI4.8/18.9 kDa (slow myosin light chain 2), pI4.8/19 kDa
(fast myosin light chain 2), pI5.0/21 kDa (fast myosin light
chain 1), pI5.2/42 kDa (actin), pI6.6/43 kDa (mitochondrial
creatine kinase), pI6.6/43 kDa (cytosolic creatine kinase),
pI9.1/22 kDa (adenylate kinase), pI6.8/20 kDa (crystallin)
and pI6.7/17 kDa (myoglobin). Fig. 8 shows a representative
2-D reference gel of the MDX gastrocnemius muscle,
outlining landmark spots of albumin, actin-·1, myosin light
chain A1-LC, tropomyosin TPM-1·, tropomyosin TPM-2ß,
fast troponin C, and the cytosolic creatine kinase (34,54).
5. Comparative proteomic analysis of muscular dystrophy
Muscular dystrophies are a group of progressive fibre-wasting
diseases with distinct mutations or rearrangements in genes
encoding essential structural or functional muscle proteins
(89). One of the most severe forms is represented by Duchenne
muscular dystrophy, which is the most frequent neuro-
muscular disorder in humans (90). A primary deficiency in the
Dp427 isoform of the membrane cytoskeletal protein
dystrophin is the underlying genetic cause of muscle
degeneration in Duchenne patients. The loss of dystrophin
causes a severe reduction in a subset of sarcolemmal proteins,
including sarcoglycans, sarcospan, dystroglycans, syntrophins
and dystrobrevins (58,91). In addition, dystrophin-associated
signaling elements, such as the neuronal isoform of the
enzyme nitric oxide synthase, are also affected in X-linked
muscular dystrophy (92). The dystrophin-glycoprotein
complex stabilizes the cellular periphery in healthy muscle
fibres by linking the extracellular matrix element laminin to
the actin membrane cytoskeleton (93). The absence of full-
length dystrophin and the reduction in dystrophin-associated
surface proteins impairs the integrity of the muscle plasma-
lemma by disturbing the trans-sarcolemmal connection. A
weakened structural support of the dystrophic sarcolemma
was shown to cause an increased frequency of membrane
micro-rupturing. Injured muscle fibres usually reseal very
quickly in a Ca2+-dependent process. In muscular dystrophy,
this natural membrane repair mechanism appears to introduce
a class of not well-characterised Ca2+-leak channels into the
dystrophic plasmalemma triggering a pathophysiological
increase of the cytosolic Ca2+-concentration (94). Elevated
Ca2+-levels are implicated in rendering fibres more susceptible
to tissue degradation via activation of proteolytic pathways
(95). Since most pathological processes exhibit a molecular
hierarchy with respect to aberrant signaling patterns and
abnormal downstream events, it is believed that the deficiency
in dystrophin and the loss of dystrophin-associated glyco-
proteins also initiates a stepwise insult to the muscular system,
eventually leading to impairment of ion homeostasis,
abnormal excitation-contraction coupling and disturbed
energy metabolism in dystrophinopathies (96,97).
An inherited one-gene disease, such as Duchenne muscular
dystrophy, that exhibits progressive pathological changes due
to abnormalities in a distinct genetic entity (98), suggests
itself for a biochemical analysis using comparative proteomic
approaches (99). However, as outlined by LeBihan and co-
workers (28), the analysis of small muscle biopsies from
genetically diverse human patients presents a technical
challenge for the proper identification of valid biomarkers of
muscle diseases. It is therefore an advantage to employ
suitable animal models for the large-scale screening of novel
disease markers of a neuromuscular disorder prior to studying
human biopsy specimens with a high degree of inter-
individual differences (100). Once reliable biomarkers have
been identified, for example by comparative chromato-
graphical or 2-D gel electrophoretic screening of mouse
models, simpler biochemical methods such as immuno-
blotting can then be used to characterise human biopsy
material. Since differences in life history, life style, gender,
age, nutrition and unrelated disease processes such as
infections, can have a major impact on the muscle protein
expression pattern in humans, this scientific approach is
easier and more reliable. In the case of dystrophinopathy, the
natural MDX mutant mouse is widely employed as an animal
model which exhibits severe muscular degeneration in the
diaphragm (101). Muscle fibres from the MDX mouse
exhibit, in analogy to human muscular dystrophy, a primary
genetic abnormality in the dystrophin isoform Dp427 (102), a
concomitant reduction in the dystrophin-associated glyco-
protein complex (103), drastically elevated levels of serum
creatine kinase (104), segmental fibre necrosis (105), an
increased susceptibility to osmotic shock (106), stretch-
induced injury (107) and an abnormal excitation-contraction-
relaxation cycle (108-110). This makes MDX muscles not
only a suitable system to study novel therapeutic strategies,
but also to identify new biomarkers of X-linked muscular
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Figure 8. Illustration of 2-D landmark gel spots from crude skeletal muscle
extracts. In order to judge the proper extraction and gel electrophoretic
separation of muscle proteins, the position and relative size of abundant 2-D
landmark spots is extremely useful. Shown is a silver-stained 2-D gel of the
total gastrocnemius muscle extract from the dystrophic mouse model MDX.
The position of easily detectable isoforms of albumin, actin, tropomyosin,
troponin, myosin and the cytosolic creatine kinase is indicated. The pH-
values of the first dimension gel system and molecular mass standards (in
kDa) of the second dimension are indicated on the top and on the left of the
panels, respectively.
dystrophy. In order to directly compare normal versus
dystrophic MDX samples, conventional Hot-Coomassie and
silver-staining in combination with 2-D spot pattern software
analysis has been used (34,56,81,82), as well as the more
discriminatory fluorescence DIGE method (35). 
Fig. 8 illustrates the silver-stained 2-D protein spot
pattern of dystrophic MDX limb muscle fibres and Fig. 5B-G
shows the comparative DIGE analysis of the MDX
diaphragm muscle. Our recent studies (34,35,56), in addition
to the published work by Ge et al (81,82) have established a
reduction in adenylate kinase, calsequestrin and regucalcin
and a concomitant increase in the small heat shock protein
cvHSP in MDX fibres. The usefulness of the fluorescence
tagging method is clearly apparent from the enlarged images
of the 2-D spot representing the cytosolic Ca2+-binding
protein regucalcin. While the comparison of the large protein
gels in Fig. 5B-D does not show major differences in the
overall spot pattern between normal and dystrophic diaphragm
fibres, fluorescence images focusing on the area of 30-50 kDa
and pI 4-6 demonstrate a drastic reduction in the regucalcin
protein species with an approximate molecular mass of
33.9 kDa and an estimated pI-value of 5.2 (Fig. 5E-G). The
DIGE technique resulted in the detection of approximately
2,400 individual 2-D diaphragm muscle protein spots (35),
which makes this technique several fold more sensitive than
comparative proteomics employing Hot-Coomassie or silver
staining. A statistically significant decrease in the expression
of 21 muscle proteins was be shown in the MDX diaphragm
using the DIGE technique, which included dihydrolipoamide
dehydrogenase, adenylate kinase, the Fbxo11-protein, and
ß-hemoglobin. In contrast, the density of 14 diaphragm
proteins was drastically increased. This included cardiac and
muscle myosin heavy chains, the heat shock proteins cvHSP
and chaperonin, as well as aldehyde reductase, desmin, and
vimentin (35). Hence, the lack of plasmalemmal integrity
appears to cause a generally perturbed protein expression
pattern in dystrophic muscle fibres, which might initiate
severe disturbances of ion homeostasis and signal trans-
duction mechanisms (58,96,97). Notably, the observed up-
regulation of the small heat shock protein cvHSP suggests
that increased expression of stress elements seems to be an
essential cellular response in the dystrophic phenotype (111).
The pharmacological induction of muscle-specific heat shock
proteins could therefore represent a novel therapeutic strategy
approach to reverse the muscle degeneration process in
inherited neuromuscular disorders (35,112) or support
myoblast transfer approaches (113).
6. Proteomic profiling of sarcopenia of old age
Although muscle aging can be partially prevented by regular
exercise and proper nutritional support, the progressive loss
of skeletal muscle mass and strength is one of the most striking
features of the senescent organism (44-46). The all-embracing
term for the age-related muscle-wasting syndrome has now
been generally accepted as being sarcopenia of old age (45).
While the majority of aging humans experience, at least
initially, a relatively mild form of sarcopenia, severe forms of
age-dependent muscular atrophy present serious muscle
pathology (44). With the drastic increase in the average life
expectancy in developed countries, clinical sarcopenia in the
very old may lead to frailty and pronounced functional
impairment and therefore represents a major challenge to
health services (46). Aging can be defined as the progressive
loss or function of a biological system, which is accompanied
by decreasing fertility and increasing mortality. Biological
aging has to be considered as a natural progressive decline in
body systems. It represents a fundamental biological process
that seems to be intrinsic to almost all cellular systems,
including muscle tissues.
The role of aging in nature and the evolutionary
mechanisms that are associated with the senescence process
are poorly understood but intensively debated. The major
hypotheses of aging include four main ideas, i.e. the
‘programmed senescence’ hypothesis, the ‘mutation
accumulation’ hypothesis, the ‘antagonistic pleiotropy’
hypothesis and the ‘disposable soma’ hypothesis (114). In
order to understand the functional decline in muscle strength
in the elderly, these suggested biological mechanisms might
be valid starting points to initiate proteomic profiling studies
to elucidate the biochemical mechanisms that lead to senescent
muscular atrophy. Possibly, genes that specifically trigger the
aging process have evolved in order to limit population size.
Acceleration of the turnover of generations may then aid in the
adaptation of organisms to drastically changed environmental
conditions. In contrast, the so-called ‘selection shadow’ at
old age may permit an accumulation of deleterious mutations
causing biological aging. This might trigger for example
oxidative stress in the peripheral nervous system, thereby
affecting the innervation pattern of skeletal muscles. Genetic
pleiotropy is the production of two or more, apparently
unrelated, biological effects by a single gene. If pleiotropic
genes benefit organisms early in life, they should be favoured
by evolutionary selection. If the same genes have negative
effects at later stages, they may cause molecular senescence,
such as muscle wasting. 
For an individual organism, the metabolic resources for
biological maintenance and cellular repair are limited. The
overall evolutionary pressure on a specific biological system
is therefore probably limited to keep it in proper conditions
for optimum survival (114). Thus, senescence may be a result
of a bioenergetic trade-off between somatic cells versus germ
line maintenance. In biological terms, there has to be an
optimum distribution of limited metabolic resources between
somatic maintenance and reproduction. Aging in animals
appears to occur almost exclusively in protected environments
and not under natural conditions. Comparative studies of
wild and domesticated animal species suggest that the recent
dramatic increase in human longevity is probably closely
connected to improved hygiene, better shelter from exposure
thereby preventing thermogenesis, vastly superior nutrition,
better general health care and unprecedented advances in
medical and pharmacological treatments of major diseases,
especially infectious disorders (114). If this idea reflects
correctly the biological phenomena of human aging, disorders
of senility such as sarcopenia may be classified as clinical
artifacts that would not occur under natural conditions (115).
This hypothesis is obviously controversial and certainly covers
up the fact that aging is a fundamental biological process, in
the same way as fertilization or cellular differentiation.
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Independent from this purely biological perspective of the
role of aging during human evolution, sarcopenia is a real
and very serious clinical problem in the aging population and
warrants large-scale biochemical analyses such as MS-based
proteomics. 
In developing new treatment strategies for counteracting
age-related muscle degeneration, it is of central importance
to analyse the molecular pathogenesis of the entire aging
process (116). This would include epidemiological, clinical,
histological, anatomical, genetic, molecular biological, cell
biological, physiological and biochemical approaches (117).
Comparative proteomics suggests itself as the initial method
of choice, since it can be employed in an analytical high-
throughput mode and be used to determine potential changes
in protein expression levels at the entire protein complement
level. This gives proteomic approaches a great advantage
over more restrictive biochemical investigations of the
past, which have focused on particular types of proteins or
individual pathways that may be involved in fibre
degeneration. In conjunction with transcriptomics, proteomic
aging research has the real potential to make a decisive step
forward in our understanding of the cellular aging process
and may elucidate the molecular mechanisms that underlie
the pathological changes that lead to age-dependent functional
impairments (118-121). However, the rationalisation of the
pathobiochemical hierarchy within intrinsic hazards that lead
to cellular aging will be extremely difficult. Complex
biological processes are associated with sarcopenia, such
as oxidative stress, impaired cellular repair, mutation
accumulation and genetic degeneration. Proteomic profiling
can only be a starting point to identify new biomarkers of the
age-dependent decline in muscle strength. Once novel
disease proteins have been established, only a detailed bio-
chemical, physiological and cell biological characterisation
can define their exact role in sarcopenia. Initial findings from
an ongoing long-term proteomic study on the protein
composition of aged human muscles have demonstrated that
approximately 60% of fibre protein species are shared between
individuals (16). The remaining proteins are believed to
represent inter-individual differences and these molecular
adaptations may reflect differences that decisively determine
the degree and time line of the muscle aging process. These
kinds of detailed comparative studies with large cohorts of
individual muscle proteomes may lay the foundation for
establishing bio-gerontology as one of the most important
fields in modern biology and clarify the role of senescence in
nature.
Since the age-associated loss of muscle mass and its
functional consequences are due to a variety of molecular
and cellular changes, and such complex pathological changes
cannot be studied in their entirety by conventional bio-
chemistry, proteomic screening may be the best way to
uncover new protein factors that are primarily involved in
sarcopenia. Many physiological, biochemical and cellular
abnormalities have already been described to be associated
with muscle aging, whereby it is difficult to decipher if a
molecular pathological hierarchy and/or interdependence
between the various metabolic insults exist (116,117). The
most obvious abnormalities in aged skeletal muscle fibres are
a general loss of active motor units, a shift to a slower
twitching fibre type and progressive denervation (122-124).
As reviewed by Carlson et al (125), the consequences of
natural muscle aging and experimental denervation are very
similar on the cell biological level. Hence, pathological
changes in the peripheral nervous system may play a more
important role in age-related muscle wasting, as for example
intrinsic fibre changes due to a true muscle-specific defect.
Since gene expression and protein isoform concentration
patterns in skeletal muscle are greatly influenced by fibre
loading and neuromuscular activity, this idea is a valid
hypothesis to explain certain aspects of sarcopenia. A strong
indicator that partial denervation or abnormal neuronal
transmission plays a central role in aging muscle pathology is
presented by the biochemical analysis of experimentally-
stimulated aged fibres (126,127). The biological potential of
young versus old muscle to adapt to a physiological challenge,
such as chronic low-frequency stimulation, is very comparable.
The alterations in the metabolic enzyme profile of conditioned
young and old skeletal muscles did not show a significant
difference (127). Thus, skeletal muscles themselves appear
not to age drastically, but the nerve-muscle connection is
intrinsically involved in the fate of a motor unit-associated
group of fibres. In addition, an altered equilibrium of growth
factors and hormones important for the maintenance of proper
muscle function, modified gas and metabolite exchange rates
due to decreased capillarisation, disturbed physiological ion
handling leading to abnormal ion homeostasis, decreased
protein synthesis of contractile and regulatory muscle proteins,
a general progressive decline in energy intake, specific
abnormalities in energy supply to fibres based on mito-
chondrial alterations, extensive oxidative stress, increased
triggering of apoptotic pathways, abnormal metabolic
regulation and a decreased availability of satellite cells, have
all been implicated in rendering muscles more susceptible to
sarcopenia (128-136).
In human muscle aging, the loss of biological integrity and
metabolic homeostasis shows considerable inter-individual
differences. Although the detailed study of these biological
variations may be helpful in determining alternative pathways
to adapt to intrinsic and/or extrinsic cellular hazards, the
enormous complexity of changes may make it very difficult
to properly differentiate between primary and secondary
effects. Thus, the initial usage of established inbred animal
models may be the best way to identify new biomarkers by
proteomics and then use specific probes, such as monoclonal
antibodies, to investigate the fate of these proteins in more
detail in aging human skeletal muscles. Recent proteomic
studies with aged rat muscle tissues show that this is a valid
approach. Schoeneich and co-workers (84,85) showed that
nitration of key muscle proteins may be involved in the
functional decline of motor unit function. That the age-
dependent nitration of muscle proteins is deleterious to fibre
physiology has been shown for the relaxation-inducing Ca2+-
ATPase of the sarcoplasmic reticulum (137). In analogy to
these earlier biochemical studies, the proteomic profiling of
aged muscle fibres revealed the nitration of essential
metabolic enzymes, such as aldolase, enolase, glycer-
aldehyde-3-phosphate dehydrogenase, triosephosphate
isomerase, succinate dehydrogenase and creatine kinase
(84,85). Since the constant exposure of fibres to high levels
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of nitric oxide and superoxide triggers the formation of
peroxynitrate, nitration of tyrosine residues occurs in both
young and old muscles. However, nitrated protein species
appear to accumulate at an accelerated rate in senescent
fibres, which may be due to more nitration and/or drastically
reduced rates of protein turnover in aged skeletal muscles.
The increased presence of nitrotyrosine in muscle proteins
is usually associated with a decline in biological activity
and could therefore play a central role in age-dependent
dysfunction of muscle. 
Piec et al (87) and Gelfi et al (88) have recently
performed a proteomic survey of aged rat and human muscle,
respectively, which identified the differential expression of
various muscle components. Aged fibres exibited a severely
disturbed protein expression pattern including a modified
concentration of contractile elements such as myosin light
chains, actin and troponins, the cytoskeletal proteins desmin
and tubulin, and various regulatory proteins. This shows that
aging has a profound effect on many key processes in muscle,
including the functioning and regulation of the contractile
apparatus, as well as the cytoskeletal network. 
7. Proteomics of skeletal muscle transformation
Slow versus fast muscle fibres may exhibit different degrees
of susceptibility to pathological insults and fibre type shifting
has been shown to be associated with certain degenerative
muscle disorders. For example, fast fibres are believed to be
earlier affected in muscular dystrophy and changes in fibre
type composition appear to be a feature of age-induced
muscle wasting (43). Under normal physiological conditions,
adaptations to changed neuromuscular activity also trigger
subtle fibre type shifting (19,20). Traumatic injuries to
muscles initiate the proliferation of the fibre-specific stem
cell pool, the muscle satellite cell population. The subsequent
motor neuron activity dictates the differentiation pattern of
the newly fused fibres, forming motor units between the
nerve and its associated group of multi-nucleated muscle
cells (17). Therefore, it is crucial to understand the molecular
and cellular mechanisms that underlie the formation and
maintenance of the differently contracting fibres. An ideal
experimental model system for studying the graded responses
of skeletal muscles to enhanced neuromuscular activity under
conditions of maximum activation is presented by external
chronic low-frequency stimulation. As reviewed by Pette and
Staron (22), the physiological and biochemical characterisation
of this system has elucidated three main cellular processes
during the fast-to-slow transition period. Firstly, a certain
degree of fibre transformation is due to true trans-differen-
tiation from a fast-twitching to a slower-contracting fibre
phenotype. Secondly, satellite cells are recruited and
differentiate according to the changed pattern of innervation.
Thirdly, cellular destruction and regeneration occurs involving
especially the fastest contracting glycolytic fibre population.
The final physiological results of long-term low-frequency
stimulation are muscles that exhibit smaller caliber cells with
an elevated aerobic-oxidative capacity and a higher resistance
to fatigue (20). Physiologically, the most striking feature of
transformed fibres is a drastic increase in the half-relaxation
time and the time-to-peak twitch tension (138). Stimulation-
induced fibre type shifting is also reflected by alterations in
the combinatorial isoform expression pattern of key muscle
proteins, including contractile elements such as the myosin
heavy chains, ion-regulatory proteins such as Ca2+-pumps,
Ca2+-channels and Ca2+-binding proteins, and various
metabolic enzymes, transporters, signaling elements and
receptors (22,139-141). 
The traditional method of investigating fibre type shifting
on the biochemical level is to focus on individual protein
species, metabolic pathways or physiological processes
(18-20,22). Since this is an extremely laborious approach
that lacks a comprehensive dimension, comparative proteomics
suggests itself as the method of choice for future muscle
transformation studies. Because MS methodologies in
combination with suitable dye staining techniques can
determine the fate of hundreds to thousands of muscle proteins
in one experimental step, the proteomic profiling of electro-
stimulated fibres promises exiting new insights into the
biology of muscle differentiation. In addition to many other
muscle research groups involved in muscle proteomics
(Table I), our laboratory is currently involved in the systematic
identification and cataloging of muscle proteins that can be
DORAN et al:  SKELETAL MUSCLE PROTEOMICS560
Figure 9. Immunoblotting survey of biomarkers of the fast and slow muscle
phenotype. Shown are 2-D immunoblots, focusing on the area of immuno-
decoration, that have been labeled with antibodies to the fast-twitch
SERCA1 isoform of the sarcoplasmic reticulum Ca2+-ATPase (A), the slow-
twitch SERCA2 isoform of the sarcoplasmic reticulum Ca2+-ATPase (B),
the fast-twitch CSQf isoform of the terminal cisternae Ca2+-binding protein
calsequestrin (C), the slow-twitch CSQs isoform of the terminal cisternae
Ca2+-binding protein calsequestrin (D), the Ca2+-shuttle element
sarcalumenin (SAR) of the sarcoplasmic reticulum (E), the enzyme
glyceraldehyde-phosphate dehydrogenase (GAPDH) (F) and phospho-
fructo-kinase (PFK) (G). Lanes 1 and 2 represent extracts from the rabbit
tibialis anterior (TA) and soleus (SOL) muscle, respectively.
employed as biomarkers of fibre type changes. Over the last
few decades it has been established that skeletal muscles are
highly versatile and extremely plastic, so that their contractile
properties are highly adaptable to changed functional
demands (18). The first comprehensive proteomic analysis of
fast versus transformed fibres has confirmed that enhanced
contractile activity due to chronic low-frequency stimulation
causes an array of functional, structural and metabolic
alterations in order to adapt to altered physiological
requirements (54). The differential protein expression pattern
in fast versus slow fibres shown in the 2-D immunoblotting
survey in Fig. 9 was observed to a comparable degree in
unstimulated versus transformed fibres. In agreement with the
proteomic profiling of fast versus slow muscle populations
(66-69), the immunoblotting survey of biomarkers of the fast
and slow muscle phenotype presented here demonstrates that
the fast and slow isoforms of the sarcoplasmic reticulum
Ca2+-ATPase and the terminal cisternae Ca2+-binding protein
calsequestrin are reliable indicators of fibre type distribution.
In addition, the expression of enzymes such as glycer-
aldehyde-phosphate dehydrogenase is a good marker for
shifts from a glycolytic to a more oxidative metabolism
(Fig. 9).
The recent proteomic profiling of chronic low-frequency-
stimulated tibialis anterior muscles using conventional
Coomassie staining of 2-D gels revealed that 16 major
muscle protein species underwent a drastic alteration in their
expression levels during the fast-to-slow transition process
(54). This agrees with the drastic alterations in protein
expression patterns between unstimulated versus electro-
stimulated fast muscles as illustrated by fluorescence DIGE
analysis (Fig. 5A). Changes in skeletal muscle bio-markers
suggest that the transformation of easily fatiguing white
fibres into fatigue-resistant red fibres is associated with a
conversion of the contractile apparatus to isoforms with
slower twitch characteristics, the optimum utilization of free
fatty acids via increased albumin transportation, a
rearrangement of the creatine kinase isozyme pattern for
enhanced mitochondrial activity, an increased availability of
oxygen for aerobic metabolism via myoglobin transport, and
the up-regulation of stress proteins for stabilising myo-
fibrillar components with chaperones (54). A striking finding
of the proteomic strategy was a drastic increase in the
abundance of albumin and the mitochondrial marker enzyme
creatine kinase. This indicates that the enhanced transportation
of fatty acids and increased mitochondrial metabolism are
important prerequisites for successful fast-to-slow fibre
transformation. A reduction in the density of glycolytic
enzymes, such as enolase and aldolase, and a concomitant
increase in the oxygen-carrier myoglobin clearly argues in
favour of a shift from a glycolysis-dominated bioenergetic
process to more oxidative metabolism in conditioned muscles.
Changes in the contractile apparatus were reflected by
distinct switches in the fast and slow isoforms of troponin
and myosin light chain (54). Hence, the proteomic profiling
of conditioned muscles has clearly shown that chronic
electro-stimulation changes the isoform expression pattern of
the contractile machinery, the regulatory excitation-contraction
coupling apparatus, the luminal and cytosolic ion homeostasis
complex and metabolic pathways. Future experiments using
the DIGE technique with a higher sensitivity will be employed
to refine these results and will hopefully lead to a better
understanding of fibre type shifting in normal and pathological
muscle fibres.
8. Future perspectives
For future studies into the cause of age-related or inherited
muscle diseases, proteomics is an excellent way of determining
an initial picture of differential protein expression patterns in
normal versus diseased tissues (142). Although current
protein chemical separation techniques do not achieve a
complete presentation of all protein species from a given
proteome, the near-to-total proteome approach is the most
suitable and the most advanced biotechnological tool
available to determine changes leading to skeletal muscle
pathologies. Intraproteomics analysis is an excellent approach
to evaluating abnormal protein complex formation. Despite
the fact that homogenous preparations of monomeric proteins
or peptides can often perform enzymatic reaction cycles,
under in vivo conditions most biological macromolecules do
not exist in isolation but act as multi-functional entities
within supra-molecular assemblies. Thus, if one defines
individual peptide species as the basic units of an ensemble
of proteins related to a genome, then heterogeneous protein
complexes actually form the functional units of biochemistry
and cell biology. This gives intraproteomic studies into the
quaternary structure of supramolecular complexes a central
place in modern biochemical research. If due to the
complexity of mammalian cells, homogenization technology
does not result in the preparation of suitable extracts, then
subproteomics is the method of choice. It is, however,
important to be aware of the introduction of artifacts during
subcellular fractionation protocols. Hence, the future success
of subproteomic approaches will depend on the development
of improved subcellular fractionation techniques, advances in
protein separation methods, a better combination of quick
assays for protein identification and the establishment of
faster protein-protein interaction assays. 
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